Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II basket trial of niraparib + dostarlimab in DNA repair-deficient or platinum-sensitive solid tumors
2020-002766-14Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib and dostarlimab in Nonhematologic neoplasms and cancer, sponsored by Gustave Roussy. Primary endpoint: Overall Response Rate (ORR) according to RECIST v1.1. Started Aug 2020; status: active.
02
Drugs
niraparibdostarlimab
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on 2020-002766-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002766-14.